Corrigendum to “Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy” [Neuromuscular Disorders 26/9 (2016) 576–583] (S0960896616300761) (10.1016/j.nmd.2016.05.016));Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy

Neuromuscular Disorders

Volumn 26, Issue 9, 2016, Pages 576-583

  Mercuri, Eugenio ^a   Signorovitch, James Edward ^w,x   Swallow, Elyse ^w   Song, Jinlin ^w   Ward, Susan J ^x   Pane, M ^a   Mazzone, E ^a   Messina, S ^b   Vita, G L ^b   Sormani, M P ^c   D'Amico, A ^d   Berardinelli, A ^e   Magri, F ^f   Comi, G P ^g   Baranello, G ^h   Mongini, T ⁱ   Pini, A ^j   Battini, R ^k   Pegoraro, E ^l   Bruno, C ^m   Politano, L ⁿ   Previtali, S ^o   Binks, M H ^p,q   Campion, G ^p,r   Charnas, L ^p,s   Kaye, E ^p,t   Kelly, M ^p,u   Morris, C ^p,q   Reha, A ^p,v   more..

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^e C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^f Seconda Universit di Napoli   (United States)

^g Policlinico   (Italy)

^h DEPARTMENT OF NEUROSURGERY   (Italy)

ⁱ UNIVERSITY OF TURIN   (Italy)

^j RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^k DEPARTMENT OF DEVELOPMENTAL NEUROSCIENCE   (Italy)

^l UNIVERSITY OF PADOVA   (Italy)

^m G GASLINI INSTITUTE   (Italy)

ⁿ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^o SAN RAFFAELE HOSPITAL   (Italy)

^p Pfizer Inc ^*

^q PFIZER INC   (United States)

^r BIOMARIN PHARMACEUTICAL INC   (United States)

^s SHIRE   (United States)

^t AVI BIOPHARMA INC   (United States)

^u Cure Duchenne   (United States)

^v PTC THERAPEUTICS   (United States)

^w ANALYSIS GROUP   (United States)

^x The TAP Collaboration   (United States)

more..

Author keywords

Ambulatory function; Duchenne muscular dystrophy; Latent class trajectory analysis; Natural history; Variability

Indexed keywords

STEROID;

6 MINUTE WALK DISTANCE; ADOLESCENT; AMBULATORY CARE; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE COURSE; DUCHENNE MUSCULAR DYSTROPHY; HUMAN; INTENTION TO TREAT ANALYSIS; ITALY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; AGE; CLASSIFICATION; DISEASE EXACERBATION; EXERCISE TEST; FOLLOW UP; GENETICS; PATHOPHYSIOLOGY; PRESCHOOL CHILD; WALKING;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; EXERCISE TEST; FOLLOW-UP STUDIES; HUMANS; MALE; MUSCULAR DYSTROPHY, DUCHENNE; RETROSPECTIVE STUDIES; STEROIDS; WALKING;

EID: 84979538874     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2017.01.004     Document Type: Erratum

References (34)

1. [1] Hoffman, E.P., Brown, R.H. Jr, Kunkel, L.M., Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51 (1987), 919–928.
2. [2] Emery, A.E.H., Muntoni, F., Quinlivan, R., Duchenne muscular dystrophy. Oxford monographs on medical genetics, 4th ed, 2015, Oxford University Press, Oxford 308 p; ix.
3. [3] Ricotti, V., Ridout, D.A., Scott, E., et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 84 (2013), 698–705.
4. [4] Pane, M., Fanelli, L., Mazzone, E.S., et al. Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: a multicentric longitudinal study using the Performance of Upper Limb test. Neuromuscul Disord 25 (2015), 749–753.
5. [5] Mazzone, E., Bianco, F., Main, M., et al. Six minute walk test in type III spinal muscular atrophy: a 12 month longitudinal study. Neuromuscul Disord 23 (2013), 624–628.
6. [6] Seferian, A.M., Moraux, A., Annoussamy, M., et al. Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne muscular dystrophy: an observational multicenter trial. PLoS ONE, 10, 2015 e0113999.
7. [7] McDonald, C.M., Henricson, E.K., Abresch, R.T., et al. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve 48 (2013), 343–356.
8. [8] Goemans, N., van den Hauwe, M., Wilson, R., van Impe, A., Klingels, K., Buyse, G., Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids. Neuromuscul Disord 23 (2013), 618–623.
9. [9] Pane, M., Mazzone, E.S., Sormani, M.P., et al. 6 minute walk test in Duchenne MD patients with different mutations: 12 month changes. PLoS ONE, 9, 2014 e83400.
10. [10] Pane, M., Mazzone, E.S., Sivo, S., et al. Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes. PLoS ONE, 9, 2014 e108205.
11. [11] Voit, T., Topaloglu, H., Straub, V., et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol 13 (2014), 987–996.
12. [12] Bushby, K., Finkel, R., Wong, B., et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 50 (2014), 477–487.
13. [13] McDonald, C.M., Henricson, E.K., Han, J.J., et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve 41 (2010), 500–510.
14. [14] Mazzone, E., Vasco, G., Sormani, M.P., et al. Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology 77 (2011), 250–256.
15. [15] McLaughlin, K.A., King, K., Developmental trajectories of anxiety and depression in early adolescence. J Abnorm Child Psychol 43 (2015), 311–323.
16. [16] Tielemans, S.M., Geleijnse, J.M., Menotti, A., et al. Ten-year blood pressure trajectories, cardiovascular mortality, and life years lost in 2 extinction cohorts: the Minnesota Business and Professional Men Study and the Zutphen Study. J Am Heart Assoc, 4, 2015, e001378.
17. [17] Pietrzak, R.H., Lim, Y.Y., Ames, D., et al. Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of ageing. Neurobiol Aging 36 (2015), 1231–1238.
18. [18] Leoutsakos, J.M., Bandeen-Roche, K., Garrett-Mayer, E., Zandi, P.P., Incorporating scientific knowledge into phenotype development: penalized latent class regression. Stat Med 30 (2011), 784–798.
19. [19] Shiyko, M.P., Li, Y., Rindskopf, D., Poisson growth mixture modeling of intensive longitudinal data: an application to smoking cessation behavior. Struct Equ Modeling 19 (2012), 65–85.
20. [20] Muthen, B., Brown, H.C., Estimating drug effects in the presence of placebo response: causal inference using growth mixture modeling. Stat Med 28 (2009), 3363–3385.
21. [21] Hunter, A.M., Muthen, B.O., Cook, I.A., Leuchter, A.F., Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder. J Psychiatr Res 44 (2010), 90–98.
22. [22] Mazzone, E.S., Pane, M., Sormani, M.P., et al. 24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. PLoS ONE, 8, 2013 e52512.
23. [23] Laboratories ATSCoPSfCPF, ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166 (2002), 111–117.
24. [24] McDonald, C.M., Widman, L.M., Walsh, D.D., Walsh, S.A., Abresch, R.T., Use of step activity monitoring for continuous physical activity assessment in boys with Duchenne muscular dystrophy. Arch Phys Med Rehabil 86 (2005), 802–808.
25. [25] Muthen, B., Shedden, K., Finite mixture modeling with mixture outcomes using the EM algorithm. Biometrics 55 (1999), 463–469.
26. [26] Muthen, B., Muthen, L.K., Integrating person-centered and variable-centered analyses: growth mixture modeling with latent trajectory classes. Alcohol Clin Exp Res 24 (2000), 882–891.
27. [27] Proust-Lima, C., Dartigues, J.F., Jacqmin-Gadda, H., Joint modeling of repeated multivariate cognitive measures and competing risks of dementia and death: a latent process and latent class approach. Stat Med 35 (2016), 382–398.
28. [28] Akaike, H., A new look at the statistical model identification. IEEE Trans Automat Contr, 19, 1974.
29. [29] Schwarz, G., Estimating the dimension of a model. Ann Stat 6 (1978), 461–464.
30. [30] McDonald, C.M., Henricson, E.K., Abresch, R.T., et al. The 6-minute walk test and other clinical endpoints in Duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 48 (2013), 343–356.
31. [31] van den Bergen, J.C., Hiller, M., Bohringer, S., et al. Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants. J Neurol Neurosurg Psychiatry 86 (2015), 1060–1065.
32. [32] Bello, L., Kesari, A., Gordish-Dressman, H., et al. Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study. Ann Neurol 77 (2015), 684–696.
33. [33] Willcocks, R.J., Arpan, I.A., Forbes, S.C., et al. Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: effects of age and disease progression. Neuromuscul Disord 24 (2014), 393–401.
34. [34] Forbes, S.C., Willcocks, R.J., Triplett, W.T., et al. Magnetic resonance imaging and spectroscopy assessment of lower extremity skeletal muscles in boys with Duchenne muscular dystrophy: a multicenter cross sectional study. PLoS ONE, 9, 2014 e106435.